TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01070511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
Study: NCT02919514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training on sand surface.
Description: Physical training on sand surface.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training on soft surface.
Description: Physical training on soft surface.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training on soft surface.
Description: Physical training on soft surface.
Study: NCT04424693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tdap Vaccine Administration
Description: Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
Study: NCT03817814

Intervention type: BEHAVIORAL
Intervention: web-based questionnaire
Description: Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
Study: NCT01446744

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
Study: NCT03335280

Intervention type: DRUG
Intervention: 68Ga-citrate PET/MR
Description: Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.

Intervention type: DRUG
Intervention: 68Ga-citrate PET/MR
Description: Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
Study: NCT04338737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timming of feeding
Description: post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
Study: NCT01446744

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative radiotherapy
Description: Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice
Study: NCT04338737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timming of feeding
Description: post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timming of feeding
Description: post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
Study: NCT04277039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic treatment + cognitive training
Description: This intervention is a combination of manipulative osteopathic treatment and cognitive training to be administered each week for a 12-week study period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic treatment
Description: manual treatment using osteopathic procedure. 8 sessions for a 12 week study period

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: administration of non-steroid inflammatory drug according to international guidelines
Study: NCT03897595

Intervention type: DEVICE
Intervention: MPact Cup
Description: Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
Study: NCT03009968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-void residual free voiding trial
Description: Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
Study: NCT02215005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Study: NCT01108198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate cream
Description: Study cream was applicated once per day for 4-8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate cream
Description: Study cream was applicated once per day for 4-8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moisturizing cream
Description: study cream was applicated once per day for 4 to 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moisturizing cream
Description: study cream was applicated once per day for 4 to 8 weeks
Study: NCT02242383

Intervention type: DRUG
Intervention: Telmisartan

Intervention type: DRUG
Intervention: Telmisartan in combination with hydrochlorothiazide
Study: NCT02259894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00730548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device triggered remote telephone contact because of Care Alert
Description: Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
Study: NCT04071418

Intervention type: RADIATION
Intervention: 3D-printing Template-assisted CT-guided I-125 Seeds Implantation
Description: (1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
Study: NCT04933461

Intervention type: DEVICE
Group type: OTHER
Intervention: Safety lancet
Description: There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.

Intervention type: DEVICE
Group type: OTHER
Intervention: Safety lancet
Description: There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
Study: NCT01163214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection
Description: Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
Study: NCT00857077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04470089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myramistin
Description: Oromucosal application
Study: NCT04046731

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin Testing
Description: Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
Study: NCT02762331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Comparing safety and efficacy of IV Vitamin C in CABG patients
Study: NCT04524013

Intervention type: OTHER
Intervention: There is no intervention. It is an observational study.
Description: There is not intervention
Study: NCT02762331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention
Study: NCT02055300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pristiq
Study: NCT04518488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.

Intervention type: OTHER
Group type: OTHER
Intervention: Informational Support Group (Control group)
Description: The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
Study: NCT04591847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 2
Description: Vitamin D2 20000IU 1 tab oral weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo drug
Description: Placebo drugs 1 tab oral weekly
Study: NCT03212456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid-free group
Description: We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Group
Description: This group will receive fentanyl in the induction of anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominal plane block with ropivacaine
Description: The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominal plane block with placebo
Description: the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
Study: NCT01431963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal
Description: No comparison.
Study: NCT02790424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging devices
Description: technological adjustment tests
Study: NCT03326622

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate exercise
Description: A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
Study: NCT00376896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008 200mcg
Description: GW876008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008 20mcg
Description: GW876008 20mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00951912

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g soy protein isolated per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daidzein
Description: 50mg daidzein +10g soy protein isolated per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein
Description: 50mg genistein +10g soy protein isolated per day
Study: NCT04717856

Intervention type: OTHER
Group type: OTHER
Intervention: screening: HCV RNA test and risk factors questionaire
Description: Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
Study: NCT02250586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-CSO
Description: Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
Study: NCT03099811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive plan
Description: The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation
Description: Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
Study: NCT03988465

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT03949894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: 30mg and 15mg of Tolvaptan Tablet
Study: NCT01156246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
Study: NCT03822689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F2220
Description: M: Folding D: 22mm; L: 2.0M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F2220
Description: M: Folding D: 22mm; L: 2.0M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F2216
Description: M: Folding; D: 22mm; L:1.6M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F2216
Description: M: Folding; D: 22mm; L:1.6M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F1520
Description: M: Folding; D: 15mm; L:2.0M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F1520
Description: M: Folding; D: 15mm; L:2.0M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F1516
Description: M: Folding; D: 15mm; L:1.6M
Study: NCT03822689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F1516
Description: M: Folding; D: 15mm; L:1.6M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube U1016
Description: M: Unfolding; D: 10mm; L:1.6M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube U1016
Description: M: Unfolding; D: 10mm; L:1.6M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube U1516
Description: M: Unfolding; D: 15mm; L:1.6M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube U1516
Description: M: Unfolding; D: 15mm; L:1.6M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube CA20
Description: M: Co-axis; L:2.0M
Study: NCT04470089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myramistin
Description: Oromucosal application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Myramistin
Description: Oromucosal application
Study: NCT04293718

Intervention type: OTHER
Intervention: papillary gum biopsies
Description: 1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
Study: NCT03471442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
Study: NCT03822689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube CA20
Description: M: Co-axis; L:2.0M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube CA16
Description: M: Co-axis; L:1.6M

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube CA16
Description: M: Co-axis; L:1.6M
Study: NCT01700855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3\~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate.
Study: NCT04833621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES GROUP
Description: The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES GROUP
Description: The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed
Study: NCT03900000

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
Study: NCT03040466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reusable fiberoptic ureteroscope
Description: We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
Study: NCT04484610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain
Description: Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
Study: NCT03040466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable digital ureteroscope
Description: We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
Study: NCT04278547

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISPOT IFN-γ assay
Description: ELISPOT IFN-γ diagnostic test: Evaluation of specific cellular immune response against the IE-1 antigen and the CMV pp65, using the technique ELISPOT IFN-γ and individualize the preventive strategy according to the result. In patients with a ELISPOT of low risk will be made advance therapy (preemptive therapy) guided by PCR of CMV In patients with a high risk ELISPOT, universal prophylaxis with valganciclovir will be performed oral (900 mg / 24h) or intravenous ganciclovir (5-10 mg / Kd / day) in case the oral route is not available.
Study: NCT00203294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine, bupivicaine and saline
Description: lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine plus bupivicaine plus triamcinolone (steroid)
Description: lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
Study: NCT00485615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 Joy enteric coated concentrated fish oil
Description: 1500-3000mg; one per day